Brent Bluett, Alexander Y Pantelyat, Irene Litvan, Farwa Ali, Diana Apetauerova, Danny Bega, Lisa Bloom, James Bower, Adam L Boxer, Marian L Dale, Rohit Dhall, Antoine Duquette, Hubert H Fernandez, Jori E Fleisher, Murray Grossman, Michael Howell, Diana R Kerwin, Julie Leegwater-Kim, Christiane Lepage, Peter Alexander Ljubenkov, Martina Mancini, Nikolaus R McFarland, Paolo Moretti, Erica Myrick, Pritika Patel, Laura S Plummer, Federico Rodriguez-Porcel, Julio Rojas, Christos Sidiropoulos, Miriam Sklerov, Leonard L Sokol, Paul J Tuite, Lawren VandeVrede, Jennifer Wilhelm, Anne-Marie A Wills, Tao Xie, Lawrence I Golbe
Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS; the most common phenotype of corticobasal degeneration) are tauopathies with a relentless course, usually starting in the mid-60s and leading to death after an average of 7 years. There is as yet no specific or disease-modifying treatment. Clinical deficits in PSP are numerous, involve the entire neuraxis, and present as several discrete phenotypes. They center on rigidity, bradykinesia, postural instability, gait freezing, supranuclear ocular motor impairment, dysarthria, dysphagia, incontinence, sleep disorders, frontal cognitive dysfunction, and a variety of behavioral changes...
2021: Frontiers in Neurology